Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;21(1):104.e1-5.
doi: 10.1016/j.cmi.2014.08.005. Epub 2014 Oct 13.

Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

M Alvarez  1 , S Monge  2 , N Chueca  1 , V Guillot  1 , P Viciana  3 , L Anta  4 , C Rodriguez  5 , J L Gomez-Sirvent  6 , G Navarro  7 , I de los Santos  8 , S Moreno  9 , F García  10 ; Cohorte de la Red de Investigación en Sida
Affiliations
Free article

Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

M Alvarez et al. Clin Microbiol Infect. 2015 Jan.
Free article

Abstract

We characterized transmitted drug resistance to rilpivirine and the predicted efficacy of first-line rilpivirine-containing regimens in antiretroviral-naive Spanish patients. International Antiviral Society-USA mutations were detected in 138 of 2781 patients (4.9%), E138A (3.4%) being the most prevalent. Using the Stanford Algorithm, 121 patients (4.4%) showed low-level or intermediate resistance. No differences in the predicted efficacy of first-line non-nucleoside reverse transcriptase inhibitor-based regimens were observed. As rilpivirine becomes more widely used in clinical practice, the evolution of its transmitted drug resistance will need to be monitored. In addition, the exact role of E138A singletons on rilpivirine activity as part of first-line regimens merits further evaluation.

Keywords: Naive adults; resistance mutations; rilpivirine; therapeutic barrier.

PubMed Disclaimer

Publication types